Enlivex Therapeutics Ltd.
ENLV · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $81 | $85 | $90 | $36 |
| Gross Profit | -$81 | -$85 | -$90 | -$36 |
| % Margin | – | – | – | – |
| R&D Expenses | $1,484 | $2,141 | $2,550 | $3,419 |
| G&A Expenses | $0 | $937 | $954 | $1,957 |
| SG&A Expenses | $992 | $937 | $954 | $1,957 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$85 | -$90 | $256 |
| Operating Expenses | $2,476 | $2,993 | $3,414 | $5,632 |
| Operating Income | -$2,557 | -$3,078 | -$3,533 | -$5,632 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $352 | $1,210 | $81 | $456 |
| Pre-Tax Income | -$2,205 | -$1,868 | -$3,452 | -$5,176 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2,205 | -$1,868 | -$3,452 | -$5,176 |
| % Margin | – | – | – | – |
| EPS | -0.092 | -0.078 | -0.16 | -0.24 |
| % Growth | -17.1% | 51.1% | 33.3% | – |
| EPS Diluted | -0.092 | -0.078 | -0.16 | -0.24 |
| Weighted Avg Shares Out | 24,046 | 23,856 | 21,895 | 21,895 |
| Weighted Avg Shares Out Dil | 24,046 | 23,856 | 21,895 | 21,895 |
| Supplemental Information | – | – | – | – |
| Interest Income | $352 | $1,210 | $81 | $456 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $81 | $85 | $90 | $36 |
| EBITDA | -$2,124 | -$2,993 | -$3,414 | -$5,140 |
| % Margin | – | – | – | – |